UK markets close in 6 hours 59 minutes

MRK Jun 2025 90.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
44.100.00 (0.00%)
As of 09:38AM EDT. Market open.
Full screen
Previous close44.10
Open44.10
Bid0.00
Ask0.00
Strike90.00
Expiry date2025-06-20
Day's range44.10 - 44.10
Contract rangeN/A
Volume1
Open interestN/A
  • Yahoo Finance Video

    FDA approves Merck treatment for lung disease, potential path to upside

    The Food and Drug Administration has approved Winrevair, Merck's (MRK) latest drug to treat pulmonary arterial hypertension, a lung condition. Investors have been anxiously awaiting the approval as the company is set to lose its patent for Keytruda. The drug will help to reduce the risk of death and worsening events in patients by 84%. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to discuss how the treatment could offer a potential path to the upside for Merck. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's Note: This article was written by Gabriel Roy

  • Reuters

    US STOCKS-Stocks close with gains, led by Dow as investors look for rate insight

    U.S. stocks were higher on Wednesday, with the Dow leading gains and the S&P 500 setting a closing record, paced drugmaker Merck, while investors looked towards the next piece of inflation data and Federal Reserve commentary for signals on the rate path. Merck & Co advanced 4.96% as the best performer on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition.

  • Reuters

    US STOCKS-Stocks gain, led by Dow as investors look for rate insight

    U.S. stocks were higher, with the Dow leading gains on Wednesday, and the S&P 500 setting a closing record, paced by gains in drugmaker Merck, while investors looked towards the next piece of inflation data and Federal Reserve policymaker commentary for signals on the rate path. Merck & Co advanced as the best performer on the Dow after the U.S. Food and Drug Administration approved its therapy for adults suffering from a rare lung condition. The blue-chip Dow sits roughly 1% away from breaking the 40,000 level for the first time.